Literature DB >> 20682142

Intrauterine device use among women with uterine fibroids: a systematic review.

Lauren B Zapata1, Maura K Whiteman, Naomi K Tepper, Denise J Jamieson, Polly A Marchbanks, Kathryn M Curtis.   

Abstract

BACKGROUND: There are concerns that intrauterine device (IUD) use by women with uterine fibroids might increase their uterine bleeding or risk for device expulsion. The objective of this systematic review was to evaluate evidence concerning the safety and effectiveness of IUD use among women with uterine fibroids. Key questions included whether IUD use is associated with increased risk for uterine bleeding among women with uterine fibroids and whether the presence of uterine fibroids is associated with an increased risk for device expulsion among IUD users. STUDY
DESIGN: We searched the PubMed database for peer-reviewed articles relevant to IUD (copper or levonorgestrel-releasing) use and uterine fibroids published in any language from database inception through June 2009. We used standard abstract forms and a grading system to summarize and assess the quality of the evidence.
RESULTS: From 202 articles found in the database search, we identified 11 studies that met our inclusion criteria, all of which examined outcomes among users of the levonorgestrel-releasing IUD (LNG-IUD). Evidence from 10 of 11 noncomparative studies (Level II-3, fair) suggests that LNG-IUD use among women with fibroids does not increase menstrual bleeding, and results from all 11 showed that menstrual blood loss decreased among women who continued to use the LNG-IUD through the end of the study period. Overall, serum levels of hemoglobin, hematocrit and ferritin increased among LNG-IUD users in studies that assessed these outcomes. Several studies reported some occurrences of irregular bleeding. Findings from two cohort studies (Level II-2, fair to poor) showed rates of LNG-IUD expulsion to be higher among women with uterine fibroids (11% in each) than among women without uterine fibroids (0% and 3%); however, in one study the difference was not statistically significant, and in the other significance testing was not conducted. Six prospective noncomparative studies reported expulsion rates of 0-20% among women with uterine fibroids.
CONCLUSIONS: Most women with uterine fibroids are likely to have less menstrual blood loss and higher serum levels of hemoglobin, hematocrit and ferritin after insertion of an LNG-IUD, despite some occurrences of irregular bleeding. LNG-IUD users with uterine fibroids may have higher rates of expulsion than those without fibroids. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20682142     DOI: 10.1016/j.contraception.2010.02.011

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Progestogens or progestogen-releasing intrauterine systems for uterine fibroids (other than preoperative medical therapy).

Authors:  Ussanee S Sangkomkamhang; Pisake Lumbiganon; Porjai Pattanittum
Journal:  Cochrane Database Syst Rev       Date:  2020-11-23

Review 2.  Efficacy and safety of long-acting reversible contraception.

Authors:  Amy Stoddard; Colleen McNicholas; Jeffrey F Peipert
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

Review 3.  Uterine leiomyomas: individualizing the approach to a heterogeneous condition.

Authors:  Shannon K Laughlin; Elizabeth A Stewart
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

Review 4.  The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.

Authors:  Oliver Pohl; R Howard Zobrist; Jean-Pierre Gotteland
Journal:  Reprod Sci       Date:  2014-09-16       Impact factor: 3.060

5.  Are women satisfied when using levonorgestrel-releasing intrauterine system for treatment of abnormal uterine bleeding?

Authors:  Nina Mansukhani; Jyothi Unni; Meenakshi Dua; Reeta Darbari; Sonia Malik; Sohani Verma; Sonal Bathla
Journal:  J Midlife Health       Date:  2013-01

Review 6.  Current medical treatment of uterine fibroids.

Authors:  Geum Seon Sohn; SiHyun Cho; Yong Man Kim; Chi-Heum Cho; Mee-Ran Kim; Sa Ra Lee
Journal:  Obstet Gynecol Sci       Date:  2018-02-13

Review 7.  Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids.

Authors:  Nicoletta Biglia; Silvestro Carinelli; Antonio Maiorana; Marta D'Alonzo; Giuseppe Lo Monte; Roberto Marci
Journal:  Drug Des Devel Ther       Date:  2014-02-20       Impact factor: 4.162

Review 8.  The role of levonorgestrel intrauterine systems in the treatment of symptomatic fibroids.

Authors:  Wojciech Wrona; Anna Stępniak; Piotr Czuczwar
Journal:  Prz Menopauzalny       Date:  2017-12-30

Review 9.  Uterine Fibroids: Burden and Unmet Medical Need.

Authors:  Ayman Al-Hendy; Evan Robert Myers; Elizabeth Stewart
Journal:  Semin Reprod Med       Date:  2017-11-03       Impact factor: 1.303

Review 10.  Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?

Authors:  Funlayo Odejinmi; Reeba Oliver; Rebecca Mallick
Journal:  Womens Health (Lond)       Date:  2017-11-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.